Biogen Idec to add 100 jobs in North Carolina as revenues grow; Pharmacyclics' Imbruvica wins another indication; BMS and J&J get HIV drug approvals;

@FiercePharma: European regulators chart record year for new animal health products. More | Follow @FiercePharma

@EricPFierce: GSK is moving forward with its new API plant in Scotland. Story | Follow @EricPFierce

> Biotech Biogen Idec ($BIIB), which reported a 40% jump in 2014 revenues Thursday to $9.7 billion, intends to add about 100 employees to the 1,300 it already has at its facility in Research Triangle Park, NC. Story

> The U.S. Food and Drug Administration Thursday expanded the use of Pharmacyclics ($PCYC) cancer fighter Imbruvica to include people with Waldenström's macroglobulinemia (WM), a rare form of cancer that begins in the body's immune system. Release

> Sanofi-Synthelabo India has bought a 20% stake in a chain of diabetes clinics in India for 90 crore ($14.5 million). Report

> Abbott Laboratories' ($ABT) CEO Miles White says his company is better protected than some from the foreign exchange effects of a stronger dollar, projecting it will reduce sales by about 6% this year. Story

> The FDA on Thursday approved fixed-dose HIV meds from Johnson & Johnson ($JNJ) and Bristol-Myers Squibb ($BMY), both in combination with a boosting agent made by Gilead Sciences ($GILD). Story

> German Merck ($MRK) today announced that it had named Andreas Stickler, 43 Head of Controlling of the Healthcare Business Sector. Release

Medical Device News

@FierceMedDev: Stomach-draining obesity startup gets $12M in debt to support PMA in mid-2015. More | Follow @FierceMedDev

@EmilyWFierce: Roche and Qualcomm join forces for next-gen remote patient monitoring system. Story | Follow @EmilyWFierce

> Wall Street buys into third med tech IPO of the week: Avinger. More

> J&J to distribute Insuline diabetes device in Russia to stem flagging diabetes care sales. News

> China medical device market to top Japan to claim No. 2 spot globally. Report

Biotech News

@FierceBiotech: Obama wants $215M to kick off 'precision medicine' project. More | Follow @FierceBiotech

@JohnCFierce: $ICPT up 38% this a.m., which is nuts. Article | Follow @JohnCFierce

@DamianFierce: The to-my-knowledge guest list for tomorrow's White House precision medicine thing: $FMI, $VRTX, $MRK, $REGN. | Follow @DamianFierce

> Obama wants $215M to kick off 'precision medicine' project. Story

> Pfizer bails on a $70M rare disease deal with Repligen. More

> Spark nails a $161M IPO to fund its 'breakthrough' gene therapy. News

And Finally... Vivus ($VVUS) Friday announced that the European Commission approved its erectile dysfunction drug Spedra as the first ED treatment that can be effective 15 to 30 minutes before sexual activity. Release

Suggested Articles

It’s been a rocky road for BMS’ immuno-oncology duo in previously untreated lung cancer, but a new addition to the regimen might hold the ticket.

Novartis’ Zolgensma launch has been anything but boring: First a record price, then a data scandal and now a manufacturing-related delay in Europe.

As CEO Paul Hudson focuses Sanofi's R&D program on immuno-oncology and gene therapies, Sanofi is readying a vaccine plant to make viral vectors.